Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Paris - Delayed Quote EUR

OSE Immunotherapeutics SA (OSE.PA)

Compare
5.16
-0.35
(-6.35%)
At close: April 4 at 5:35:29 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for OSE.PA

Recent News: OSE.PA

View More
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025
GlobeNewswire 3 days ago
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire 11 days ago
OSE announces overall survival success in Phase II PDAC vaccine trial

OSE announces overall survival success in Phase II PDAC vaccine trial
Clinical Trials Arena 25 days ago
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer
GlobeNewswire 26 days ago
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
GlobeNewswire last month
OSE’s UC therapy prompts 16% clinical remission after ten weeks

OSE’s UC therapy prompts 16% clinical remission after ten weeks
Clinical Trials Arena last month
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
GlobeNewswire last month
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
GlobeNewswire last month
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
GlobeNewswire 2 months ago
OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
GlobeNewswire 2 months ago
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer
GlobeNewswire 2 months ago
View More

Related Tickers

ALVAL.PA Valbiotis SA
1.0700
+1.90%
 
ADOC.PA Adocia SA
3.3900
-9.60%
 
POXEL.PA Poxel S.A.
0.2140
-9.89%
 
2HA.MU Spero Therapeutics Inc
0.5750
-10.99%
 
5KW.F SkinBioTherapeutics plc
0.2620
-6.43%
 
HQ1.MU Oruka Therapeutics Inc. R
8.25
-6.25%
 
HPHA.F Heidelberg Pharma AG
2.6500
-6.03%
 
CAMX.ST Camurus AB (publ)
541.50
-4.16%
 
22Z.SG Zealand Pharma A/S
58.30
-6.65%
 
ALTHX.PA Theranexus Société Anonyme
0.4300
-0.46%